Otezla Divestiture Announcement
In anticipation of the acquisition of Celgene by Bristol-Myers Squibb and the impending divestiture of our lead inflammation asset to Amgen, no funding requests related to dermatology, rheumatology and Behcet’s Disease will be accepted after Wednesday, October 30, 2019. Check back on this site periodically for instructions on how to submit future requests to Amgen for these disease areas.
Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide.
Celgene supports this mission by providing support for Independent Medical Education (IME) grants and Scientific Advancement Grants (SAG). The Scientific Education department accepts applications for both educational and scientific advancement programs that are independently developed and targeted to US clinical and scientific professionals.
For more specific information and how to submit a grant request, please see more information in the funding categories below or to submit a grant application please select either “log-in” or “register now” for new users.
Funding provided for independent medical education programs (live and enduring activities) for US Healthcare Professionals which may be accredited or non-accredited and which aim to address knowledge or clinical practice gaps and improve patient care.
Funding provided to support initiatives that aim to advance knowledge or understanding of clinical science, scientific techniques or information, or patient outcomes.
For other funding types, please visit our funding page.